Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 11,464 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 11,464 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $23.10, for a total transaction of $264,818.40. Following the sale, the chief financial officer now owns 23,382 shares of the company’s stock, valued at $540,124.20. This trade represents a 32.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Mark Ragosa also recently made the following trade(s):

• On Wednesday, March 19th, Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA traded up $0.47 during midday trading on Wednesday, hitting $23.08. 396,095 shares of the company traded hands, compared to its average volume of 405,125. The stock has a 50-day moving average of $20.16 and a 200-day moving average of $22.08. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.56 and a one year high of $28.15. The firm has a market cap of $1.68 billion, a P/E ratio of -164.85 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same quarter in the prior year, the company earned $0.35 earnings per share. The company’s quarterly revenue was up 46.9% on a year-over-year basis. Sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on KNSA shares. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $37.17.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas increased its position in shares of Kiniksa Pharmaceuticals by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock worth $215,000 after purchasing an additional 719 shares during the last quarter. Martingale Asset Management L P increased its position in shares of Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Martingale Asset Management L P now owns 49,360 shares of the company’s stock worth $976,000 after purchasing an additional 900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after purchasing an additional 1,100 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in shares of Kiniksa Pharmaceuticals by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company’s stock worth $457,000 after purchasing an additional 1,374 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.